Literature DB >> 7873466

Clinical pharmacokinetics of nitrates.

M G Bogaert1.   

Abstract

The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873466     DOI: 10.1007/bf00877116

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  62 in total

Review 1.  Organic nitrate esters: clinical use and mechanisms of actions.

Authors:  J Ahlner; R G Andersson; K Torfgård; K L Axelsson
Journal:  Pharmacol Rev       Date:  1991-09       Impact factor: 25.468

2.  The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.

Authors:  A H Thomson; S H Miller; S T Green; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].

Authors:  G Menke; R Schnellhammer; N Rietbrock
Journal:  Arzneimittelforschung       Date:  1987-11

4.  The sorption of nitroglycerin by infusion sets.

Authors:  D De Rudder; J P Remon; E N Neyt
Journal:  J Pharm Pharmacol       Date:  1987-07       Impact factor: 3.765

5.  Influence of intravenous administration set composition on the sorption of isosorbide dinitrate.

Authors:  C De Muynck; F Colardyn; J P Remon
Journal:  J Pharm Pharmacol       Date:  1991-09       Impact factor: 3.765

Review 6.  Nitrates in the elderly. Pharmacological considerations.

Authors:  J G Kelly; K O'Malley
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

7.  Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system.

Authors:  T Huber; P G Merz; S Harder; N Rietbrock
Journal:  Arzneimittelforschung       Date:  1990-12

8.  Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.

Authors:  R A Lefebvre; G De Wilde; M T Rosseel; D Duprez; J De Sutter; F Pocchiari
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.

Authors:  K Nakatsu; J F Brien; G Savard; E B Toffelmire; H Abdollah; B M Bennett; G S Marks
Journal:  Biopharm Drug Dispos       Date:  1992-07       Impact factor: 1.627

View more
  6 in total

1.  Novel pharmacokinetic modelling of transdermal nitroglycerin.

Authors:  B Auclair; G Sirois; A H Ngoc; M P Ducharme
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  Regioselectivity of nitroglycerin denitration by flavoprotein nitroester reductases purified from two Pseudomonas species.

Authors:  D S Blehert; K L Knoke; B G Fox; G H Chambliss
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

Review 3.  Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites.

Authors:  Satoru Hashimoto; Atsuko Kobayashi
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.

Authors:  L F Ferrari; J D Levine; P G Green
Journal:  Neuroscience       Date:  2016-01-11       Impact factor: 3.590

6.  Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis.

Authors:  Li-Ming Shao; Qing-Yu Chen; Miao-Yan Chen; Jian-Ting Cai
Journal:  Dig Dis Sci       Date:  2009-01-22       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.